Chief, Early Drug Development Service
I am a gynecologic medical oncologist and Chief of the Early Drug Development Service. In my clinical practice, I specialize in caring for women with gynecologic cancers including ovarian, endometrial (uterine), and cervical cancers. In addition, I lead a large multidisciplinary group of researchers that conduct a variety of early phase clinical studies where we study new drugs entering the clinic for the first time. My research focuses on the development of genomically selected targeted therapies. I have developed and led numerous global clinical trials of these genetically targeted cancer therapies, leading to eventual approval of several of these new drugs as routine therapies.
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by David Hyman
Clinical Trials Co-Investigated by David Hyman
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicare and New York State Medicaid also provide benefits for care at MSK.Learn more